skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8838

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation

Review

(2700) Views  (961) Full article downloads

Authors: Gerald V Naccarelli, Frank Peacock

Published Date September 2009 Volume 2009:5 Pages 783 - 791
DOI: http://dx.doi.org/10.2147/VHRM.S7616

Gerald V Naccarelli,1 Frank Peacock2

1Penn State Heart and Vascular institute, Hershey, Pennsylvania, USA; 2Cleveland Clinic, Cleveland, Ohio, USA

Abstract: Atrial fibrillation (AF) is the most common form of cardiac arrhythmia and is associated with an increased risk of cardiovascular morbidity and mortality, especially due to ischemic stroke. The occurrence of AF leads to atrial electrical and structural remodeling. The renin-angiotensin system appears to play a role in the development of atrial arrhythmias by its involvement in both of these processes. Large-scale hypertension trials and heart failure trials have indicated the potential value of angiotensin II receptor blockers in the treatment of AF.

Keywords: angiotensin II receptor blockers, atrial fibrillation, cardiac arrhythmia








Readers of this article also read:

Safety and efficacy of rosiglitazone in the elderly diabetic patient
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Comparative assessment of angiotensin receptor blockers in different clinical settings
Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure
Effectiveness of coordination exercise in improving cognitive function in older adults: a prospective study
Erratum
Effect of vascular burden as measured by vascular indexes upon vascular dementia: a matched case-control study
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University